Management ChangeJul 23, 2026, 07:02 AM
Veraxa Biotech Appoints Christoph Erkel as New CSO
AI Summary
Veraxa Biotech AG announced the appointment of Christoph Erkel, Ph.D., as its new Chief Scientific Officer, effective immediately. Dr. Erkel, previously the company's Vice President of Research & Development, will lead the acceleration of Veraxa's proprietary BiTAC® platform technologies to develop advanced cancer treatments. He brings 20 years of experience in antibody therapeutics and succeeds Rick Austin, Ph.D., who is departing the company.
Key Highlights
- Veraxa Biotech appointed Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO), effective immediately.
- Dr. Erkel was previously Vice President of Research & Development at Veraxa.
- He will direct and accelerate the development of the company's proprietary BiTAC® platform technologies.
- The goal is to develop safer and more effective cancer treatments for patients with solid tumors.
- Dr. Erkel has 20 years of expertise in antibody therapeutics, bridging early-stage discovery and clinical readiness.
- He succeeds Rick Austin, Ph.D., who will be leaving the company after a transition period.
Price Impact
More from VRXA